Business
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
TOKYO, February 25, 2026--Japan approves Alpha DaRT for head & neck cancer, becoming the first market outside Israel.
About this update from Alpha Tau Medical Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3187,"height":1114,"url":"https://media.zenfs.com/en/business-wire.com/e0adde7d72dfa55ffa7f3578986ee125"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QpDutrRC2VhQX4F_JhhsAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e0adde7d72dfa55ffa7f3578986ee125","width":960,"height":336},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/tThAUxBXOXcqCO4jvIp0Tw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04Mzg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e0adde7d72dfa55ffa7f3578986ee125","width":1200,"height":419}},"lazy":false},{"type":"text","content":"Offering a New Option for Head and Neck Cancer Treatment","length":56,"tagName":"p"},{"type":"text","content":"TOKYO, February 25, 2026--(BUSINESS WIRE)--HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device ‘Alpha DaRT (Diffusing Alpha Radiation Therapy),’ developed by Alpha Tau Medical Ltd. (Headquarters: Jerusalem, Israel) has received official approval in Japan. HekaBio led the approval process as the Designated Marketing Authorization Holder (DMAH) and will be responsible for launching the product in the Japanese market.With this approval, Japan becomes the first country in the world outside of Israel to approve Alpha DaRT. The product will be available in Japan for the treatment of unresectable locally advanced or recurrent head and neck cancer, offering a new therapeutic option for cases where conventional treatments have been insufficient.We would like to express our sincere appreciation to Dr. Jun Itami, who was affiliated with the National Cancer Center Hospital during the clinical trial and is currently serving as Director of the High-Precision Radiation Therapy Center at Shin-Matsudo Central General Hospital, as well as to all healthcare professionals for their valuable contributions throughout the approval process.","length":1188,"tagName":"p"},{"type":"text","content":"Alpha DaRT: Technology, Mechanism of Action and Efficacy","length":56,"tagName":"p"},{"type":"text","content":"Alpha DaRT involves inserting sources containing Ra-224(1) atoms fixed in a medical grade stainless-steel tube into solid tumors. As Ra-224 decays, daughter nuc...